LB PHARMACEUTICALS INC
LBRXNasdaq
$31.41
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↑ +81.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$887.1M
Enterprise Value
$521.4M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$39.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-10.3%
ROIC
—
Debt / Equity
—
Net Cash
$365.6M
Return 1Y
—
Earnings
LBRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.67↓ -95.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | -$63.1M | -$25.2M |
| Diluted EPS | -$176.15 | -$3.13 |
| Operating cash flow | -$53.1M | -$35.2M |
| Free cash flow | -$53.8M | -$35.3M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$27.6M | -$14.2M | -$5.1M | -$5.3M | -$4.9M | -$3.6M | -$11.5M | -$19.1M |
| Diluted EPS | — | -$39.49 | — | -$14.79 | — | -$0.61 | — | -$0.67 |
| Operating cash flow | — | — | — | -$8.1M | — | — | — | -$23.3M |
| Free cash flow | — | — | — | -$8.1M | — | — | — | -$23.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for LBRX will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | Buy | 2,000,000 | $15.00 | $30.0M | filing |
| 2025-09-12 | Nussbaum Ran | Buy | 1,000,000 | $15.00 | $15.0M | filing |
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. | Buy | 1,000,000 | $15.00 | $15.0M | filing |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | Buy | 666,666 | $15.00 | $10.0M | filing |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Buy | 332,566 | $15.00 | $5.0M | filing |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | Buy | 767 | $15.00 | $11,505.00 | filing |
| 2025-09-12 | Nussbaum Ran | C | 411,681 | — | — | filing |
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. | C | 411,681 | — | — | filing |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. | C | 686,138 | — | — | filing |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | C | 547,648 | — | — | filing |
| 2025-09-12 | Vida Ventures GP III, L.L.C. | C | 1,262 | — | — | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.